Chongqing Intracerebral Hemorrhage Study

Recruiting

Phase N/A Results N/A

Trial Description

The Chongqing intracerebral hemorrhage study is a multi-center, prospective, observational study led by professor Qi Li from Chongqing Medical University. Professor Peng Xie will be the senior consultant for the study. The Chongqing intracerebral hemorrhage study will focus on the epidemiology, natural history, pathogenesis, laboratory, radiological aspects, clinical outcomes and the effects of treatment in patients with intracerebral hemorrhage.
The clinical, laboratory, imaging, genetic and outcome data of patients diagnosed with acute intracerebral hemorrhage will be prospectively collected. The prognosis of patients with intracerebral hemorrhage will be assessed by using several outcome measure scales at different time points.

Detailed Description

The Chongqing intracerebral hemorrhage study will try to address several key issues in ICH. The baseline clinical data including demographic, disease severity scores, prior drug history and relevant medical history, premorbid mRS scores will be prospectively recorded. The admission and follow-up imaging data of all registered patients will be saved as Dicom format for future use and review. The functional outcomes will be assessed and recorded by experienced neurologists.

Conditions

Trial Population

18 Years and older (Adult patients)

Outcomes

Type Measure Time Frame Safety Issue
Primary hematoma volume growth at 24 hours 24 hours
Secondary functional outcome at 3 months assessed by modified Ranking Scale 3 months
Secondary early neurological deterioration assessed by NIHSS score at 24 hours 24 hours
Secondary early neurological deterioration assessed by NIHSS at 48 hours 48 hours
Secondary early neurological deterioration assessed by NIHSS score 72hours
Secondary perihematoma edema volume measurement at 24 hours 24 hours
Secondary perihematoma edema volume measurement at 72 hours 72 hours
Secondary intraventricular hemorrhage growth 24 hours
Secondary major thromboembolic events 2 weeks

Sponsors